BCL9 and adrenal cortex carcinoma: Only 5.8% of the ACA cohort revealed more than a double increase of BCL9 expression levels, while 40 percents of the ACA tissues displayed a double expression upregulation, indicating that upregulation of BCL9 expression in adrenocortical carcinoma is correlated to the malignant characters.